Ligand Pharmaceuticals Incorporated LGND
314.16 USD +0.01 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
314.16 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
310.41 Day range 321.98
175.89 52-week range 326.63
- YTD
- +66.16%
- 1 year
- +50.11%
News
defenseworld.net Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average…
benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $397 to $402.
seekingalpha.com Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy Ligand Pharmaceuticals earns a BUY rating, driven by robust royalty growth and the accretive XOMA acquisition. Filspari's 85% YoY royalty growth and new FSGS indication position it as LGND's leading…
benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
benzinga.com Ligand Pharmaceuticals Q3 2026 Earnings Call Transcript Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 analyst estimate. Lowers FY2026 sales outlook from $270.000 million-$310.000 million to…
benzinga.com Ligand Pharmaceuticals Q3 Adj. EPS $2.67 Beats $2.38 Estimate, Sales $78.700M Beat $77.232M Estimate Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.38 by 12.18 percent. This is a 13.59 percent decrease over earnings…
benzinga.com Here's How Much $1000 Invested In Ligand Pharmaceuticals 20 Years Ago Would Be Worth Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 20 years by 12.04% on an annualized basis producing an average annual return of 20.96%. Currently, Ligand…
benzinga.com Here's How Much $1000 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 13.64% on an annualized basis producing an average annual return of 26.84%. Currently, Ligand…
benzinga.com Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
benzinga.com Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345 Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.- benzinga.com HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.
benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.- benzinga.com Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand…
- benzinga.com Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals…
benzinga.com If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals…- benzinga.com $100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals…
benzinga.com Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330 Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.- benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.
- benzinga.com HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358 HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $289 to $358.
- benzinga.com Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to…
- benzinga.com $100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand…
benzinga.com Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326 Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.- benzinga.com Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and announces $387 price target.
- benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $262 to $340.
benzinga.com Why Is Agenus Stock Falling on Tuesday? Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.
benzinga.com Why Is Agenus Stock Gaining Monday? Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
benzinga.com B of A Securities Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $388 B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $266 to $388.- benzinga.com Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332 Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $255 to $332.
- benzinga.com Ligand Plans $550M Convertible Notes Offering, To Use Notes Sale for Share Buybacks and Corporate Needs Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a
benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $252 to $262.
- benzinga.com Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50 vs $9.13 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to…
- benzinga.com Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the analyst consensus estimate of $1.82 by 10.44 percent. This is a 22.56 percent increase over…
- benzinga.com Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty…
- benzinga.com HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $289 HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $243 to $289.
- benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $252 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $235 to $252.
benzinga.com Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million Ligand to acquire XOMA Royalty for $739 million, raising 2026 outlook as analysts maintain Buy ratings and higher price targets.
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…- benzinga.com Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered…
benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $276 to $282.- benzinga.com HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $243 HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $239 to $243.
- benzinga.com Ligand Pharmaceuticals Partner Travere Therapeutics Wins FDA Approval For First Drug Treating Rare Kidney Disease Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for…
- benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $270 to $276.
benzinga.com Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst Bank of America starts coverage on Ligand with a Buy rating and $244 target, citing strong royalty portfolio and growth outlook.
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.- benzinga.com B of A Securities Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces Price Target of $244 B of A Securities analyst Jason Zemansky initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and announces Price Target of $244.
benzinga.com Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - benzinga.com Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $277 Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $275 to $277.
- benzinga.com Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.00-$9.00 vs $8.29 Est; Affirms FY2026 Sales Guidance of $245.000M-$285.000M vs $265.679M Est. Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.00-$9.00 to $8.00-$9.00 vs $8.29 analyst estimate. Affirms FY2026 sales outlook from $245.000 million-$285.000 million to…